Compare Quest Diagnostics Inc (DGX) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Symbotic Inc — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Symbotic Inc trades at $41.06 (market cap $5.41B). The key difference: Quest Diagnostics Inc is far larger — about 4.8× Symbotic Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| DGX | SYM | |
|---|---|---|
Market Cap | $26.21B | $5.41B |
Sector | Health | Technology |
52-Week High | $238.50 | $87.30 |
52-Week Low | $173.49 | $38.57 |
Enterprise Value | $31.97B | $3.67B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
SYM trades at $41.15, up 2.59% with recent earnings misses creating volatility. The stock shows bearish technical signals despite analyst optimism, with revenue growth of 21.7% in Q3 2026 but declining profitability margins. Recent institutional selling and insider transactions add complexity to the investment case.
Outlook remains mixed with strong revenue growth potential offset by margin pressures and recent earnings disappointments. The consensus price target of $60 suggests 46% upside, but investors face execution risks and competitive threats in the automation sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
